ArticleJournal of medical biochemistry2025
Effect of puerarin administration on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1Q/TNF-related protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (LP-PLA2) levels.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary heart disease (CHD) is a cardiovascular disease with a high incidence in elderly patients. This article aimed to evaluate the clinical efficacy of puerarin (Pue) as an adjuvant therapy in elderly patients with CHD and the effects of Pue on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1q/TNF-Related Protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (Lp-PLA2) levels. Methods: This retrospective cohort study compared two treatment approaches for CHD patients at Beijing University of Chinese Medicine Third Affiliated Hospital. Fifty-nine patients received standard treatment (5% glucose + nitroglycerin), and 59 received a new treatment (5% glucose + Pue injection). Outcomes were assessed using electrocardiograms, laboratory tests, and cardiac function evaluations. Results: Relative to the controls, the study subjects had a reduction in the number of angina episodes and an increase in exercise tolerance. In addition, the serum NLRP3 inflammasome and Lp-PLA2 distinctly decreased, and the serum CTRP3 distinctly increased in study subjects. Conclusions: The administration of puerarin as an adjuvant therapy in elderly patients with coronary heart disease demonstrated significant clinical efficacy, as evidenced by reduced angina episodes and improved exercise tolerance; this might be driven through inflammatory and lipid metabolism pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.